

**IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE**

**Applicant(s):** Thompson *et al.*

U.S. National Phase of PCT/GB00/01679

Serial No.: to be assigned

Filed: herewith

**For: Specific Binding Members for TGFβ<sub>1</sub>**

Attorney Docket No.: 28111/37903

Group Art Unit: to be assigned

Examiner: to be assigned

**“EXPRESS MAIL” Mailing Label**  
No. EL 564 460 856US.

I hereby certify that this paper (or fee) is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231, on this date,

October 30, 2001

  
Richard Zimmermann

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

The Applicants request that the documents listed on the attached Form PTO-1449 be made of official record in the above-identified application and considered by the Examiner.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.


This Information Disclosure Statement is submitted before receipt of a first Office action on the merits, and consequently should be considered by the Patent Office without payment of a fee. See 37 C.F.R. §1.97(b). However, please charge any necessary fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855. A copy of this paper is enclosed herewith.

The Commissioner is authorized to charge any fee deficiency required by this paper, or credit any overpayment, to Deposit Account No. 13-2855. A copy of this paper is enclosed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

By:

  
Mabeela R. McMillian  
Reg. No: 43,363

October 30, 2001

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
28111/37903Serial No. 10/018452  
to be assigned**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant  
Thompson *et al.*Filing Date  
herewithGroup  
to be assigned**U.S. PATENT DOCUMENTS**

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	5,571,714	11/05/96	Dasch <i>et al.</i>	435	240.27	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 97/13844	17/04/1997	WIPO				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

	Lucas, <i>et al.</i> , "The Autocrine Production of Transforming Growth Factor- $\beta_1$ During Lymphocyte Activation", <i>The Journal of Immunology</i> , <b>145</b> :1415-1422 (1990)
	Border, <i>et al.</i> , "Suppression of experimental glomerulonephritis by antiserum against transforming growth factor $\beta_1$ ", <i>Nature</i> , <b>346</b> :371-374 (1990)
	International Search Report PCT Application No. PCT/GB00/01679 mailed 29 August 2000
	Combined Search and Examination Report Under Section 17 and 18(3) mailed 28 September 2000

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.